Bayer HealthCare Celebrates 20th Anniversary of Kogenate® Product Line and 8 Billion IU Milestone at 2008 WFH World Congress

6/2/2008

Company Announces Winners of the “It’s Your Passion. Let It Out” Contest

ISTANBUL, Turkey (June 2, 2008) – Bayer HealthCare today announced the 20th anniversary of the company’s Kogenate® line of products and more than two decades of hemophilia A research, collaboration and community building at the 2008 World Federation of Hemophilia (WFH) World Congress in Istanbul, Turkey. More than 8 billion international units of Kogenate® and Kogenate® FS/KOGENATE® Bayer have been infused to date.

Kogenate® clinical trials began in May 1988 in Bonn, Germany. This advent of recombinant factor VIII technology represented a leap forward in the delivery of safe, effective treatment for people with hemophilia A. Since then, Bayer’s Kogenate® line of products has maintained a record of safety, with two decades of clinical use and no confirmed case of pathogen transmission.

“Besides celebrating an impressive 20 years of safe, effective treatment, we are celebrating the many lives that have been touched through the use of our Kogenate® line of products,” said Michael E. Mathews, general manager, hemophilia, and vice president of marketing, specialty medicine, Bayer HealthCare. “We are passionate at Bayer about improving the lives of people living with hemophilia. We are the only company with a long-acting recombinant factor VIII protein in human clinical trials. We are also creating new and innovative delivery systems that decrease the discomfort of infusion and increase convenience.”

To celebrate its 20-year milestone, Bayer launched the “It’s Your Passion. Let It Out” contest. Applicants from around the world expressed — in the medium of their choice — what they are passionate about as members of the hemophilia community. Representatives of the WFH served as contest judges and chose three entries to receive the grand prize, an all-expense-paid trip for two to the 2008 WFH World Congress. The winners are:

• Mindy Ritchie, USA, video
• Ilian Cori, Bulgaria, photography
• Diego Constantino Sossa Centurión, Argentina, essay

All contest submissions will be on display at the World Congress and will appear at events around the world in 2008.

Bayer is committed to developing innovative hemophilia A treatments and expanding scientific and clinical knowledge that improves patient care. Over the past two decades, Bayer has:

• Invested hundreds of millions of dollars in hemophilia research, clinical trials and post-marketing studies to ensure the safety and efficacy of its Kogenate® products.
• Supported local and international hemophilia patient groups such as the WFH in their advocacy and patient care initiatives.
• Supported innovative educational and training programs to improve the diagnosis and care of people with bleeding disorders around the world.
• Donated more than 30 million international units of product to countries with limited access to hemophilia treatment, bringing hope and saving lives.

Contact:
Sreejit Mohan
Bayer HealthCare
1+510-705-5477

About Kogenate® FS
Kogenate® FS (Antihemophilic Factor [Recombinant]) is a recombinant factor VIII treatment indicated for the treatment of hemophilia A. The most frequently reported adverse events were local injection site reactions, dizziness and rash. Known intolerance or allergic reactions to constituents of the preparation is a contraindication to the use of Kogenate® FS. Known hypersensitivity to mouse or hamster protein may be a contraindication to the use of Kogenate® FS. Please see the full prescribing information for important risk and use information at www.kogenatefs.co